JULIO MOIZESZOWICZ: PSICOFARMACOLOGIA
PSICODINAMICA. ASPECTOS NEUROQUIMICOS y
PSICOLOGICOS

(Psychodynamic Psychopharmacology. Neurochemical and
Psychological Aspects)

4th edition

Buenos Aires: Editorial Paidos; 1998 (1248 pages)

Reviewed by Carlos Morra

Information on Contents: The fourth edition of Psychodynamic Psychopharmacology is a text of 19 chapters presented in three sections. Section 1 is preceded by a Preface of the fourth and the Prefaces of the prior editions; and Section 3 is followed by an Appendix on Neuroimaging and Indexes (drug and subject). In this review, the full table of contents of the 4th edition is presented with the permission of the author.

Preface to fourth edition
Preface to previous editions

SECTION 1: GENERAL PSYCHOPHARMACOLOGY

Chapter 1: Introduction to Psychopharmacology and Neurobiology
Basic concepts of Psychopharmacologic Treatment
   Effect of non-specific factors on treatment
   Effect of specific factors on treatment
Basic concepts of Psychopharmacology and of Molecular Biology

Mechanism of action of psychotropic drugs

Cytoskeleton.
Membranes
Receptors
  Hetero-oligomeric or ion channel linked
  Monomeric or metabotropic (protein-coupled)
  Cytoplasmic receptor
  Enzymatic receptors

Signal Pathway
Mechanism of action according to site of action in the synapse
  Neurotransmitters
  Neuromodulators
  Immunopeptides
  Apoptosis

Psychoneurobiology of therapeutic action and side effects
  Efficacy of psychotropic drugs (genetic expression)
  Oncogenic theory (Post-synaptic cascade)
  Types of psychopharmacological response (genetic point of view)
  Secondary, adverse or side effects
  Assessment of efficacy (assessment scales for antidepressant effect)

Clinical psychoneurobiology of anxiety disorders
Clinical psychoneurobiology of impulsive-violent behavior (cholesterol levels)
Psychoneurobiology: Glosary of terms and abbreviations
References

Chapter 2: Psychoimmunoendocrinology, psychoneuroimmuno-oncology
Immunoneuropeptides
Limbic- hypothalamic–pituitary–adrenal axis
  Corticotropin-releasing hormone (CRH)
  Hypothalamic–pituitary-thyroid axis
  Hypothalamic–pituitary-somatotropic axis
  Hypothalamic–pituitary-gonadal axis
Neuroendocrine effects of psychotropic drugs
Psychoneuroimmuno-oncology

The oncologic patient

References

Chapter 3: Antipsychotics

Schizophrenia

- Therapeutic actions of antipsychotics
- Pharmacokinetics and plasma concentration
- Mechanism of action
- Classification of antipsychotic drugs
  - Clinical classification
    - Typical neuroleptics
    - Atypical neuroleptics
  - Drugs in clinical research
  - Adjuvants
- Classification based on the chemical structure
  - Phenothiazines
  - Butyrophenones
  - Others
- Treatment characteristics
  - Depression in schizophrenia
  - Treatment resistant schizophrenia

References

Chapter 4: Anxiolytics

Anguish and anxiety

- Neuroanatomical model of fear and anxiety
- Neuronal model of anxiety and fear
- The role of previous experiences
  - Conditioning fear
  - Extinction
  - Sensitization
Neurotransmitters related to anxiety and fear
Genetic predisposition in anxiety disorder
Classification of anxiolytics
   Benzodiazepines
      Pharmacokinetics
      Side effects
      High potency drugs
         Alprazolam
         Clonazepam
   Non-benzodiazepines
      Imidazopyridines
      Azapirones
      Beta-carbolines
Characteristics of treatment with benzodiazepines
References

Chapter 5: Hypnotics
Sleep-awake cycle
   Neurophysiology of Sleep
   Neurotransmission and sleep
Sleep disorders
Polysomnography (PSG)
Treatment
   Pharmacological
References

Chapter 6: Antidepressants
Introduction
Depression
   Biological theories
Mechanism of action
Classification
MAOIs
  Indications
Non-MAOIs
  Tricyclic (typical or conventional)
  Second generation
  Selective and specific
    SSRIs
      Differences
      Advantages and disadvantages
      NDRI
      SNRI
      NARI
Combined actions
  Non selective and specific (venlafaxine)
  Non selective and non-specific
    SARI - nefazodone
    NASSA - mirtazapine
  Non-conventional serotoninergic
    tianeptine
Side-effects of antidepressants
Treatment of side-effects
Alternative pharmacological treatments
  Somatic, non-pharmacological treatments
Characteristics of treatment
Management
Treatment resistant depression
References

Chapter 7: Anti-cyclic or anti-manic drugs
Treatment of bipolar disorder
  Lithium carbonate
    History
    Chemical structure
Chapter 7: Anticonvulsants and other anti-cyclic agents

History

Carbamazepine
Clonazepam
Valproic acid, valpromide
Oxcarbazepine
Lamotrigine
Gabapentine
Diphenylhydantoin
Other

References

SECTION II: PSYCHOPHARMACOLOGICAL TREATMENTS

Chapter 8: Treatment of Panic Disorder and Social Phobia

Panic disorder

Introduction
Psychoneurobiology
Neuroimaging
Treatment of panic
Panic as a chronic disorder
Chapter 9: Treatment of obsessive-compulsive disorder

Introduction

Symptomatology

Psychoneurobiology

Treatment
  Treatment resistance
  Serotoninergic syndrome
  Impulsivity in the OCD spectrum

References

Chapter 10: Psychopharmacological treatment of bulimia and anorexia nervosa

Bulimia nervosa
  Neurochemical aspects
  Endocrine aspects
  Brain structures involved

References

Anorexia nervosa.
  General aspects
  Treatment

References

Chapter 11: Psychopharmacologic treatment of borderline personality disorder

Clinical aspects

Psychoneurobiology

Treatment

References
Chapter 12: Psychopharmacological treatment of psychiatric emergencies
Introduction
Acute psychotic episodes and psychomotor agitation
Anxiety crises and attacks
Somatoform and conversion disorders
Suicidal behavior, risk and attempt
References

Chapter 13: Treatment of alcoholism
Introduction
Types
Pharmacokinetics of alcohol
Genetics of alcoholism
Psychoneurobiology of alcoholism
Pharmacologic treatment of alcohol dependence and abuse
  Management of acute intoxication
  Management of the abstinence syndrome
  Psychiatric comorbidities
  Wernicke-Korsakoff Syndrome
  Fetal syndrome

Chapter 14: Treatment of addictions
Introduction
Criteria for dependence
Disorders related
  Opioids
  Benzodiazepines
  Stimulants
    Beverages containing xanthines
    Ecstasy
    Cocaine
    Crack
Amphetamines
Hallucinogens
Cannabinoids (Marijuana)
Tobacco use
Inhalants
Psychodynamic profile of the addict
Psychiatric and laboratory correlates of addiction
References

SECTION III: SPECIAL PSYCHOPHARMACOLOGY

Chapter 15: Psychopharmacology in Children and Adolescents

Introduction
Pharmacological treatment
  Stimulants
  Antidepressants
  Antipsychotics
  Lithium carbonate
  Anxiolytics
  Anticonvulsants
  Other
Psychopathology in children and adolescents
  Developmental disorders
  Autism
  Rett’s syndrome
  Asperger’s syndrome
  Attention deficit disorder with hyperactivity
  Anxiety disorders
  Obsessive-compulsive disorder
  Mood disorders
  Schizophrenia and other psychotic disorders
  Tic disorders
Sleep disorders
Elimination disorders
Aggression and disruptive behavior disorders
Lead intoxication

References

Chapter 16: Geriatric psychopharmacology
General Aspects
Psychogeriatric history
Treatment
  Anxiety disorders
  Sleep disorders
  Depression
  Pseudo-dementia
  Bipolar illness
  Psychosis
  Dementia
    Histopathology of Alzheimer
    Etiopathogenesis
    Laboratory finding
    Neuropsychological finding testing
    Biomarkers
    Extraneuronal markers
    Neuroimaging
    Genetic anomalies
    Subtypes
    Pharmacological treatment
      Neurotransmitter dysfunction
      Neuronal metabolism disorder (Neuroprotectors)
      General considerations

References

Chapter 17: Psychopharmacology of women’s sexual cycle disorders. Premenstrual
syndrome, pregnancy and puerperium
Introduction
Premenstrual syndrome
  Treatment
Pregnancy, postpartum and puerperium
  Biological changes during pregnancy
  Maternity blues
  Postpartum depression
  Psychosis in puerperium
  Postpartum
    Major depression
    Psychotic depression
  Bipolar disorder during pregnancy and puerperium
  Use of psychotropic drugs during pregnancy and puerperium
  ECT during pregnancy
References

Chapter 18: Epidemiologic and molecular principles of genetic mental disorders
Introduction
Epidemiology: methodology
Multifactor concept of illness
Molecular genetics: methodology
  Genetics of schizophrenia
  Genetics of bipolar disorder
  Ethics of genetic knowledge use
Glossary of terms and abbreviations
References

Chapter 19: Pharmacology and treatment of Parkinson’s Disease
Introduction
Physiopathology
Etiology
Neurochemical basis of therapeutics
Pharmacological treatment

Initiation of treatment

Antiparkinson drugs
Levodopa (L-dopa)
Dopamine agonists
MAO-B inhibitors
Cholinergic blockers
Amantadine
Adjuvants

Drug holidays

Psychiatric Disorders in patients with Parkinson’s disease

Primary disorders
Secondary disorders

Perspective in the treatment of Parkinson’s disease

References

APPENDIX

Neuroimaging

INDEX

Drug (generic name)
Drug (trade names)

Subject

Reviewer’s Comment: From the 3rd edition, published in 1994 (and reprinted in 1996) to the 4th edition, published in 1998 (and reprinted in 2000), the size of the book further increased from 830 to 1248 pages and the number of chapters from 15 to 19. It also fully reverted to a single author text. The enlarged material covered in the fourth edition is divided into three Sections, from which the 1st, General Psychopharmacology and the 2nd, each include seven chapters, and the 3rd, Special Psychopharmacology, includes five. From the four added chapters, one addresses psychoimmunoendocrinology and psychoneuroimmunology; another, covers the treatment of borderline personality; a third, reviews the psychopharmacology of women’s sexual cycle disorders; and a fourth, is dedicated to epidemiologic and
molecular principles of genetic mental disorders.

Carlos Morra
August 27, 2015